BridgeBio Pharma, Inc.
NASDAQ:BBIOBiotechnology
+$0.75 today
- Market cap
- $15.20B
- Beta
- 0.97
- P/E (TTM)
- -18.1
- EPS (TTM)
- -$3.73
Volume 3.55M
Average 2.49M
BBIO Net Income
Bottom-line profit, the starting point for calculating cash from operations.
BridgeBio Pharma, Inc.NASDAQ: BBIO
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income declines year over year
Q2 FY2026 net income of $155.89M (cash outflow) fell 15.2% year over year, behind the -11.4% change in trailing-twelve-month net income. Sequentially, it fell 6.4% from the prior quarter. Over 3 fiscal years it compounded at +14.4% a year.
Context
- Net income amounted to 144.4% of revenue in FY2025, down 100.5 pp from a year earlier.
- Net income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 13 analysts of -$478.53M (-34.0%) for the fiscal year ending Dec 2026, a slowdown from the +33.4% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$155.89M-6.4% QoQ
- Last fiscal yearDec 2025
- -$724.93M+33.4% YoY
- LTMJun 2026
- -$695.45M-11.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -15.2% | -41.8% | -26.7 pp |
| 1 year | +33.4% | -34.0% | -67.4 pp |
| 3-year CAGR | +14.4% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (724.93M) USD
- Year-over-year change
- -33.4%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (724.93M) | -33.4% |
| FY2024 | 2024-12-31 | (543.35M) | +15.5% |
| FY2023 | 2023-12-31 | (643.2M) | -32.7% |
| FY2022 | 2022-12-31 | (484.65M) | +17.4% |
| FY2021 | 2021-12-31 | (586.45M) | — |
Net Income vs competitors
How BBIO compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -11.4% is the 9th highest of 11, against a peer median of +41.1%.
- Net income amounts to 97.5% of revenue for BBIO, versus a peer median of 65.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $27.6B USD | +3808.4% | +35.1% | 2.7% | |
| LTM Sep 2026 | €890.37M EUR | +482.2% | -27.9% | 73.7% | |
| LTM Jun 2026 | $807.99M USD | +353.2% | — | 16.8% | |
| LTM Jun 2026 | $695.45M USD | -11.4% | +14.4% | 97.5% | |
| LTM Mar 2026 | $608.92M USD | +10.8% | -6.7% | 91.0% | |
| LTM Sep 2026 | $546.15M USD | +113.1% | +12.2% | 56.9% | |
| LTM Jun 2026 | $511.45M USD | +6.8% | +16.3% | 14191.2% | |
| LTM Sep 2026 | $413.61M USD | +17.0% | +41.1% | 72563.2% | |
| LTM Sep 2026 | $146.22M USD | +65.1% | -57.4% | 22.5% | |
| LTM Mar 2026 | $122.54M USD | -335.9% | +4.5% | 612.7% | |
| LTM Jun 2026 | $38.38M USD | -106.1% | — | 3.8% | |
| Peer median (excluding BBIO) | — | +41.1% | +8.4% | 65.3% | |
Competitors are the stored peer set for BBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (586.45M) | (484.65M) | (643.2M) | (543.35M) | (724.93M) |
| Depreciation & Amortization | 5.84M | 6.77M | 6.49M | 6.08M | 5.43M |
| Deferred Income Tax | (30.93M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 99.51M | 91.56M | 0 | 95.8M | 133.02M |
| Change in Working Capital | (4.4M) | 28.08M | 5.06M | 32.04M | (51.06M) |
| Accounts Receivables | (19.75M) | 15.17M | 15.33M | (2.97M) | (134.72M) |
| Inventory | 19.75M | 0 | 0 | 0 | (25.31M) |
| Accounts Payables | 2.83M | (349K) | 2.78M | 1.51M | 26.61M |
| Other Working Capital | (7.23M) | 13.26M | (13.05M) | 33.5M | 82.36M |
| Other Non-Cash Items | 18.5M | (61.25M) | 103.93M | (111.3M) | 191.63M |
| Operating Cash Flow | (497.93M) | (419.49M) | (527.72M) | (520.73M) | (445.91M) |
| Capital Expenditures | (48.25M) | (6.32M) | (1.31M) | (933K) | (1.1M) |
| Acquisitions (Net) | (35M) | 0 | 0 | (140K) | 0 |
| Purchases of Investments | (643.28M) | (193.06M) | (137.26M) | (88.4M) | (28.2M) |
| Sales of Investments | 477.04M | 532.52M | 193.11M | 158.23M | 11M |
| Other Investing Activities | 48.65M | 118.5M | (503K) | (7.98M) | (6.19M) |
| Investing Cash Flow | (200.83M) | 453.15M | 54.03M | 60.78M | (24.49M) |
| Debt Repayment | 1.08B | (20.49M) | 0 | 476.58M | 385.5M |
| Common Stock Issued | 0 | 4.85M | 449.81M | 314.74M | 34.15M |
| Common Stock Repurchased | (204.75M) | (1.56M) | (6.88M) | (7.53M) | (48.28M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (138.49M) | 4.06M | 8.61M | (35.34M) | (12.08M) |
| Financing Cash Flow | 736.45M | (13.13M) | 451.54M | 748.46M | 359.29M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 37.69M | 20.52M | (22.15M) | 288.51M | (111.1M) |
| Free Cash Flow | (546.18M) | (425.82M) | (529.03M) | (521.66M) | (447.01M) |
BridgeBio Pharma, Inc.
NASDAQ:BBIO
Intrinsic Alpha fair value
Locked
Current Price
$78.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.